Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ziploc
Any idea how their EU patent applications are proceeding which would extend patent life till 2039 ?
Is there a tracker or portal where one can find updates ?
TIA
Catalent ! That's one of the manufacturer of Vascepa.
this doesn't look like AMR102 which is expected to be a fixed-dose combo of V+Statin.
EU IP protection till 2039
Anyone has clues how is this 2039 patent application proceeding?
"..legal and regulatory remedies.."
What could those regulatory remedies be ?
GSK vs TEVA : Implications for AMRN
Commentary from IPD analytics:
Read thrice but no luck. Anyways nice summary. Thanks.
One more thing is, generics will have to challenge and get court decision on R-It patents before the launch in 2029 or they may face risk of indirect infringement.
I don't know how CELG RDY Revlimid settlement is relevant here. The $50m settlement between the two is for Canada ONLY. RDY have strong non-infringement grounds in that case.
Inclisiran is Oral? The SA blogger is kiddin?
I like your analysis in general but sometimes you are bit harsh in writing.
Thanks for the reply and lecturing me
EOS
$800m is a significant number for an off patent brand. You may refer my first reply in this conversation for the context.
I mean these are still quite significant sales numbers.
Ok. But even if somebody is able to login, there would be no content as the meeting is scheduled for May 30th.
I believe the link would allow login approx 20 minutes before the meeting starts ( as the pop-up note says ).
Can u please (or some1 else) call IR guy and ask why they haven't listed the event on their website ? Will there be a replay webcast made available ?
TIA
Catty , which call u r talking about ?
I see this:
EMISPHERE TECHNOLOGIES, INC. will be hosting a Virtual Stockholder Meeting this year. The meeting will be held on Thursday, May 30, 2019 at 10:00 AM Eastern Time and stockholders of record will be able to vote and ask questions online during the meeting. If you would like to attend the virtual meeting and you have your control number, please go to www.virtualshareholdermeeting.com/EMIS2019 20 minutes prior to the start of the meeting to log in. If you came through your brokerage firm's website and do not have your control number, you can gain access to the meeting by logging into your brokerage firm's website 20 minutes prior to the meeting start, selecting the shareholder communications mailbox to link through to the meeting and the control number will automatically populate.
I think it will allow access few minutes before the meeting starts...
catty, how do you come to know about this meeting?
Weird to see that EMIS doesn't even bother to post it on the Investor Events page on their website.
No announcement for the meeting yet...
Thanks devj
Can't wait
Oops... Typo error. 14+ years I believe.
jomama, it may not be in the best interest of AZN to challenge and invalidate this patent... Instead they can use the same patent if they buy AMRN or somehow manage to get license from AMRN to use it..
Amarin on other hand, is not going to license this patent to AZN as it would harm Vascepa sales. Instead, they can take risk and fight it out to prevent invalidation.
FYI, This patent doesn't cover Vascepa. Expires in 2029.
AZN might have had different plans when they started this study, and may still do have. It doesn't make much sense stopping the study at this stage.
Hi BB, any idea what happened to Photonz Corp? If I remember correctly, they were successful in achieving 96% pure EPA and were looking to scale up. Their website is no longer active...
HD,
Zum,
Can you please share a list of Reduce-It patents (granted/application), possibly along with expiry dates ?
Curious to see how far they go beyond 2030...
TIA
JL,
Quite an interesting date as well. They haven't done a Q2 call in 2nd week of August at least in last 5 years.
We know it's coming.... a deal. Remains to be seen how big. I believe the Mylan settlement on Humira may have caused them to reconsider the terms and hence the delay.
" I think the data suggests it will be higher than that."
Is JT referring to JELIS (seems not) or the blinded event no. /rate that they have?
Didn't JZ say he was excited when Amarin was considering 3 options in 2012?
I believe you may already have answered this question before but can you plz share what pps/Mcap do you expect in case R-It fails?
Sandoz and Momenta together netted some ~200m in revenues from gCopaxone 20mg alone. 40 mg yet to kick in.
Is it fair to value momenta's gHumira at $100m?
I think it's easily worth $500m+. The $50m patent dance may not be required now in light of MYL settlement.
Mylan expects to launch in EU this year. Hard to understand why EU is not worth pursuing according to Momenta.
link
AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan
https://www.prnewswire.com/news-releases/abbvie-announces-humira-adalimumab-patent-license-with-mylan-300681743.html
No "Patent Dance"?
They can do it on the same day and still have a lot to talk about on the call.
Using an anticoagulant to promote hair growth doesn't sound exciting.